MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
128 hedge funds and large institutions have $1.47B invested in MyoKardia, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 51 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
17% more capital invested
Capital invested by funds: $1.26B → $1.47B (+$211M)
6% more funds holding
Funds holding: 121 → 128 (+7)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
12% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 51
49% less call options, than puts
Call options by funds: $6.21M | Put options by funds: $12.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$146M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.5M |
| 4 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$15M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$104M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$42.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$32.8M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$17.9M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$16.8M |
MYOK Hedge Fund Activity: Q1 2018 in Review
128 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q1 2018, worth a combined $1.47B — up 17% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MYOK positions and 12 closed out — a net gain of 9 holders — while 45 added to existing stakes and 51 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was TRV GP II, cutting an estimated $104M.
- 128 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q1 2018, up from 121 in Q4 2017.
- Funds reported $1.47B of MyoKardia, Inc. Common Stock stock for Q1 2018, up 17% quarter-over-quarter.
- 21 funds opened new MyoKardia, Inc. Common Stock positions in Q1 2018 and 12 closed out, a net change of +9 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q1 2018 was Fidelity Investments, an estimated $146M added.
- The largest MyoKardia, Inc. Common Stock seller in Q1 2018 was TRV GP II, an estimated $104M sold.
Based on aggregated 13F filings for Q1 2018.